Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

The double edged sword of bleeding and clotting from VEGF inhibition in renal cancer patients.

Sonpavde G, Bellmunt J, Schutz F, Choueiri TK.

Curr Oncol Rep. 2012 Aug;14(4):295-306. doi: 10.1007/s11912-012-0237-9. Review.

PMID:
22532265
2.

Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.

Coppin C, Kollmannsberger C, Le L, Porzsolt F, Wilt TJ.

BJU Int. 2011 Nov;108(10):1556-63. doi: 10.1111/j.1464-410X.2011.10629.x. Epub 2011 Sep 27. Review.

3.

Toxicities of targeted agents in advanced renal cell carcinoma.

Patel P, Srinivas S.

Curr Clin Pharmacol. 2011 Aug;6(3):181-8. Review.

PMID:
21827392
4.

Systemic therapy for metastatic renal cell carcinoma in treatment naïve patients: a risk-based approach.

Bukowski RM.

Expert Opin Pharmacother. 2010 Oct;11(14):2351-62. doi: 10.1517/14656566.2010.499126. Review.

PMID:
20586712
5.

Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms.

Mulders P.

BJU Int. 2009 Dec;104(11):1585-9. doi: 10.1111/j.1464-410X.2009.08987.x. Review.

6.

Pazopanib for the treatment of renal cancer.

Al-Marrawi MY, Rini B.

Expert Opin Pharmacother. 2011 May;12(7):1171-89. doi: 10.1517/14656566.2011.571206. Epub 2011 Apr 7. Review. Erratum in: Expert Opin Pharmacother. 2011 Jun;12(8):1349.

PMID:
21470066
7.

Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.

Albiges L, Salem M, Rini B, Escudier B.

Hematol Oncol Clin North Am. 2011 Aug;25(4):813-33. doi: 10.1016/j.hoc.2011.04.006. Review.

PMID:
21763969
8.

Anti-angiogenic targets in the treatment of advanced renal cell carcinoma.

Heng DY, Bukowski RM.

Curr Cancer Drug Targets. 2008 Dec;8(8):676-82. Review.

PMID:
19075590
9.

Reappraisal of the role of bevacizumab in the therapeutic strategy in advanced renal cell carcinoma.

Guillot A, Levy A, Pacaut C, Collard O, Massard C, Merrouche Y, Magné N.

Clin Genitourin Cancer. 2012 Sep;10(3):147-52. doi: 10.1016/j.clgc.2012.05.002. Epub 2012 Jul 15. Review.

PMID:
22796529
10.

Recent advances and future directions in the management of metastatic renal cell carcinoma.

Ansari J, Glaholm J, McMenemin R, James ND, Hussain SA.

Anticancer Agents Med Chem. 2010 Mar;10(3):225-35. Review.

PMID:
20184547
11.

Targeted therapies in the treatment of advanced renal cell carcinoma.

Seront E, Machiels JP.

Recent Pat Anticancer Drug Discov. 2009 Jun;4(2):146-56. Review.

PMID:
19519537
12.

Targeting growth factor and antiangiogenic pathways in clear-cell renal cell carcinoma: rationale and ongoing trials.

Hutson TE, Sonpavde G, Galsky MD.

Clin Genitourin Cancer. 2006 Dec;5 Suppl 1:S31-9. Review.

PMID:
17239282
13.

Impact of anti-angiogenic treatments on metastatic renal cell carcinoma.

Ainsworth NL, Lee JS, Eisen T.

Expert Rev Anticancer Ther. 2009 Dec;9(12):1793-805. doi: 10.1586/era.09.144. Review.

PMID:
19954291
14.

Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies.

Costa LJ, Drabkin HA.

Oncologist. 2007 Dec;12(12):1404-15. doi: 10.1634/theoncologist.12-12-1404. Review.

15.

Opportunities and obstacles to combination targeted therapy in renal cell cancer.

Sosman JA, Puzanov I, Atkins MB.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):764s-769s. Review.

16.

Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma.

Bukowski RM.

Expert Rev Anticancer Ther. 2010 May;10(5):635-45. doi: 10.1586/era.10.38. Review.

PMID:
20469994
17.

Pazopanib for the treatment of metastatic renal cell carcinoma.

Pick AM, Nystrom KK.

Clin Ther. 2012 Mar;34(3):511-20. doi: 10.1016/j.clinthera.2012.01.014. Epub 2012 Feb 16. Review.

PMID:
22341567
18.

Antiangiogenic treatments and mechanisms of action in renal cell carcinoma.

Négrier S, Raymond E.

Invest New Drugs. 2012 Aug;30(4):1791-801. doi: 10.1007/s10637-011-9677-6. Epub 2011 May 15. Review.

PMID:
21573959
19.

Kinase inhibitors in the treatment of renal cell carcinoma.

Larkin JM, Eisen T.

Crit Rev Oncol Hematol. 2006 Dec;60(3):216-26. Epub 2006 Jul 24. Review.

PMID:
16860997
20.

Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma.

Schmidinger M, Bellmunt J.

Cancer Treat Rev. 2010 Aug;36(5):416-24. doi: 10.1016/j.ctrv.2010.01.003. Epub 2010 Feb 16. Review.

PMID:
20163917

Supplemental Content

Support Center